▲ Director Lee Jeo, Bucheon Jungang Orthopedic Clinic
Bucheon Jungang Orthopedic Clinic has announced the introduction of Platelet-Rich Plasma (PRP) therapy, a regenerative treatment that utilizes a patient’s own blood to help alleviate knee osteoarthritis symptoms.
PRP therapy involves drawing the patient’s blood, centrifuging it to concentrate platelets, and injecting the PRP into the joint cavity. The platelets contain growth factors that promote cartilage regeneration and have anti-inflammatory effects, aiding in pain reduction and joint function improvement.
Unlike steroid or hyaluronic acid injections, PRP therapy uses autologous blood, which significantly reduces the risk of immune rejection or side effects. According to the Ministry of Health and Welfare’s official announcement on December 13, 2024, PRP therapy is recognized as a new medical technology, proven to have therapeutic effects lasting 6 to 12 months for patients with KL grade II–III knee osteoarthritis.
Dr. Lee Jeo, Director of Bucheon Jungang Orthopedic Clinic and Vice President of the Korean Orthopedic Society for Doctors, stated,
"With PRP therapy, we can now offer a new treatment option for patients who do not respond to conservative therapies. Proper patient assessment and choosing the right platelet concentration kit are critical to outcomes," he explained.
He added,
"Our clinic uses high-performance products from REV-MED, which are approved by Japan’s PMDA, to safely concentrate platelets and selectively regulate leukocytes (inflammation-related factors)."
Source: Hemophilia News
▲ Director Lee Jeo, Bucheon Jungang Orthopedic Clinic
Bucheon Jungang Orthopedic Clinic has announced the introduction of Platelet-Rich Plasma (PRP) therapy, a regenerative treatment that utilizes a patient’s own blood to help alleviate knee osteoarthritis symptoms.
PRP therapy involves drawing the patient’s blood, centrifuging it to concentrate platelets, and injecting the PRP into the joint cavity. The platelets contain growth factors that promote cartilage regeneration and have anti-inflammatory effects, aiding in pain reduction and joint function improvement.
Unlike steroid or hyaluronic acid injections, PRP therapy uses autologous blood, which significantly reduces the risk of immune rejection or side effects. According to the Ministry of Health and Welfare’s official announcement on December 13, 2024, PRP therapy is recognized as a new medical technology, proven to have therapeutic effects lasting 6 to 12 months for patients with KL grade II–III knee osteoarthritis.
Dr. Lee Jeo, Director of Bucheon Jungang Orthopedic Clinic and Vice President of the Korean Orthopedic Society for Doctors, stated,
"With PRP therapy, we can now offer a new treatment option for patients who do not respond to conservative therapies. Proper patient assessment and choosing the right platelet concentration kit are critical to outcomes," he explained.
He added,
"Our clinic uses high-performance products from REV-MED, which are approved by Japan’s PMDA, to safely concentrate platelets and selectively regulate leukocytes (inflammation-related factors)."
Source: Hemophilia News